$GH a recent new issue came public on 10/4/18 during a tough market environment but yet the stock has acted well. Guardant makes noninvasive blood-based cancer diagnostics tests based on proprietary technology. “The Guardant Health IPO priced 12.5 million shares at 19. That was above its estimated range of 15 to 17. Shares opened at 27.75 for an initial gain of 46%”. You can read more about HERE. $GH Industry Group is the medical services group, ranked number 17 out of 197 @IBDinvestors groups. $GH is not making money yet, but the sales have been impressive in the last four quarters; +217%, +96%, +90%, +95%.
$GH is down 3-days in a row to its 10 and 20 day moving averages, I have an interest on the long side if and only if it can get thru yesterday’s high (37.87). This is my plan; buy stop 37.97, stop-loss 37, target up.
Trade Like A Pro With the Most Powerful Stock Research Platform;